Italia markets closed

Dow Jones
38.672,53
+83,37(+0,22%)
Nasdaq
17.796,76
+107,88(+0,61%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0730
+0,0021(+0,19%)
Bitcoin EUR
61.359,23
-695,94(-1,12%)
CMC Crypto 200
1.378,52
-9,64(-0,69%)

NBIX Sep 2024 145.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

12,00

0,00

(0,00%)

In data: 03:19PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat